Although not brand new, Toremifene has been found to be as effective as Tamoxifen, in breast cancer, as a selective estrogen receptor modulator (SERM) with the added advantage of better patient tolerability and lesser adverse effects. Several drugs for this specific type of cancer have been developed but only a handful has made it to the market. In this present era, the internet has become a center for gathering information. Information about anti-breast cancer drugs is readily available with just one click. Questions regarding the effectiveness and safety profile of a particular anti-cancer drug, particularly for breast cancer, have been answered albeit somewhat lacking and needing further research on long term safety profiles.
M. S. Steiner has cited “androgen deprivation therapy” in prostate cancer patients as another potential clinical use for Toremifene Citrate. His study found that a significant increase in bone mineral density contributed to the improvement of symptoms and overall quality of life in patients with prostate cancer receiving androgen deprivation therapy.
The drug under the brand name, Acapodene, completed phase 3 clinical trial in the US in May 2010. The study was conducted by GTXi in order to evaluate the drug’s ability to prevent the incidence of prostate cancer in 1590 men with high grade prostatic intraepithelial neoplasia (PIN). Interestingly, the results of the three year study showed a risk reduction in the men treated with the drug compared to those on placebo.
The results of Steiner’s and GTix’s studies paved the way for pharmaceutical firms to explore its potential usefulness in other types of cancer.
LGM Pharma supplies Toremifene CAS# 89778-26-7 and Toremifene Citrate CAS# 89778-27-8 to its pharmaceutical clients who conduct continuing studies on this promising active pharmaceutical ingredient. With years of experience in the supply chain, the company is no novice in adhering to cGMP practices and standards. Strict quality control policies assure the company’s clients that they are receiving the correct active pharmaceutical ingredient (API) needed to attain their research goals.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.